Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

Regeneron Pharmaceuticals

These biotechs are developing innovative therapies while doing their part to combat the coronavirus.

3 Best Biotech Stocks to Buy Now

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite's Clinical Development organization across hematological malignancies and solid tumors. Ken Takeshita, MD, has decided to leave the company to pursue another opportunity at the end of February. Dr. Neumann, who joins Kite from Verastem, Inc. (also known as Ver

Kite Appoints Frank Neumann as Worldwide Head of Clinical Development

Gilead Sciences has switched to acquisitions instead of share repurchases. The company has made many deals which has saddled it with some debt, but should drive growth as well.

Gilead Sciences: Still A Good Bet

Investors liked the big biotech's Q4 update.

Why Gilead Sciences Stock Jumped Today

Gilead Sciences Inc (NASDAQ:GILD) earnings beat forecasts as sales of its antiviral drug remdesivir were boosted by its use as a treatment for coronavirus (COVID-19). Remdesivir is now treating one in two hospitalised patients in the United States, said the NASDAQ-listed drug group.

Gilead says remdesivir drug unaffected by new strains of coronavirus

Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.

Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand

Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $67.62, after a 2.73% increase. Moreover, over the past month, the stock spiked by 7.27%, but in the past year, decreased by 1.98%.

A Look Into Gilead Sciences Price Over Earnings

Gilead Sciences Inc (NASDAQ: GILD) reported revenue in the fourth quarter of $7.3 billion, reflecting a 26% increase from the prior-year period revenue total of $5.8 billion, in-line with the consensus estimate. Quarterly earnings of $2.19 came in above expectations of $2.15.

Gilead Stock Perks Up After COVID-19 Med Brings In $2.8B In 2020 Sales; Boosts Dividend by 4.4%

Without one drug, Gilead's Q4 update wouldn't have been a good one.

Here's the Key to Gilead Sciences' Q4 Earnings Beat

Gilead Sciences Inc. (NASDAQ: GILD) said on Thursday that its COVID-19 drug, Veklury, generated £1.39 billion of sales in the fiscal fourth quarter, making up 25% of the company's total quarterly revenue. In comparison, experts had forecast a lower £880 million of sales.

Gilead Sciences says Veklury sales made up 25% of the total Q4 revenue

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q4 2020 Results - Earnings Call Transcript

Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q4 Earnings and Revenues Top Estimates

Gilead Sciences beat fourth-quarter expectations Thursday as coronavirus treatment Veklury helped drive double-digit sales growth. In response, Gilead stock popped in after-hours action.

Gilead Stock Pops After Covid Drug Brings In $2.8 Billion In 2020 Sales

Shares of Gilead Sciences Inc.'s stock gained 2.1% in after-hours trading on Thursday after the drug maker surprised investors with better-than-expected sales of its COVID-19 drug Veklury during the fourth quarter of 2020.

Earnings Results: Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4

Shares of Gilead Sciences (NASDAQ:GILD) rose after the company reported Q4 results. Quarterly Results Earnings per share were up 68.46% year over year to $2.19, which beat the estimate of $2.15.

Recap: Gilead Sciences Q4 Earnings

Gilead Sciences Inc posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.

Gilead quarterly revenue rises 26% on remdesivir sales

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 4.4% in the company's quarterly cash dividend, beginning in the first quarter of 2021. The increase will result in a quarterly dividend of $0.71 per share of common stock. The dividend is payable on March 30, 2021, to stockholders of record at the close of business on March 15, 2021. Future dividends will be subject to Board approval. About

Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020. “Gilead continues to play a central role in the pandemic, with Veklury now treating one in two hospitalized patients in the United States. At the same time, we continue to meet the needs of people living with HIV, cancer, viral hepatitis and other conditions,” said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. “As

Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results

FOSTER CITY, Calif. & WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Human Rights Campaign (HRC), the nation's largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization, today announced that Gilead will provide a $3.2 million grant over two years to support communities disproportionately impacted by the HIV epidemic in the United States, particularly communities of color. Gilead will directly fund the efforts of the HRC Foundation – HRC'

Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice

AbbVie

AstraZeneca

Viatris

Bristol-Myers

Merck

Pfizer

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipelines appeared first on InvestorPlace.

7 Pharmaceutical Stocks With Compelling Pipelines

Gilead Sciences, Inc. (NASDAQ: GILD) said Monday that it has entered into a collaboration, option and license agreement with Gritstone Oncology Inc (NASDAQ: GRTS) to develop a vaccine-based immunotherapy that could serve as a curative treatment for HIV infection. What Happened: The two companies will develop a HIV-specific therapeutic vaccine using Gritstone's proprietary prime-boost vaccine platform that would use antigens developed by Gilead, the statement said.

Gilead, Gritstone Aim To Develop HIV Cure In Vaccine Collaboration

Arcus Biosciences

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus shares were still inactive in premarket trading.

Gilead buys more Arcus Biosciences stock, at a price above the record close

Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to use Gritstone's vaccine platform technology to develop a treatment for HIV. "Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone's proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead," the companies said in a statement.

Gritstone Oncology shares soar 44% premarket on news of collaboration with Gilead to develop HIV therapy

Gritstone Oncology Inc

FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead's efforts to find a curative treatment for human immunodeficiency virus (H

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure

Amgen

Biogen

Alexion Pharma

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

News for Gilead Sciences Stock (GILD)